Navigation Links
Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions
Date:6/29/2010

sult supports the therapeutic potential of inhibiting the glucagon receptor.  Glucagon is thought to play a greater role in increasing blood glucose in patients with advanced diabetes, so a glucagon receptor inhibitor should work very well in these patients.  Based on the positive data from this Phase 1 study and the therapeutic potential of a GCGR inhibitor, we are moving the program forward with a more potent GCGR antisense inhibitor," continued Dr. Bhanot.  

"Both ISIS 113715 and ISIS-GCGRRx highlight the multifaceted approach Isis employs to develop novel new drugs to treat type 2 diabetes.  We now have four drugs in our metabolic pipeline, each with a unique approach to the treatment of type 2 diabetes," added Dr. Bhanot.

Isis scientists presented new data from the Company's obesity drug discovery program, a part of Isis' metabolic disease franchise.  Isis previously reported that antisense reduction of fibroblast growth factor receptor 4 (FGFR4) lowered body weight and improved insulin sensitivity in mice, indicating that FGFR4 plays a role in the regulation of energy expenditure and body weight.  In this study, an antisense inhibitor to FGFR4 and rimonabant, an appetite-suppressing drug, were administered separately and in combination in animal models of obesity.  The study showed that antisense inhibition of FGFR4 was complementary to the CNS-based treatment, rimonabant, suggesting that the peripheral inhibition of FGFR4 in combination with other types of anti-obesity drugs could be a unique therapeutic approach for the treatment of obesity and related metabolic disorders.

"We have made substantial progress in our anti-obesity efforts over the last couple of years and are moving promising compounds closer to development.  We have adopted a unique approach in this program.  We believe that an anti-obesity drug that works
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Hospira Highlights a Year of Significant Progress at Its 2010 Annual Meeting of Shareholders
2. Abbott 2009 Global Citizenship Report Highlights Companys Progress in Redefining Responsibility
3. DUSA Pharmaceuticals, Inc.(R) to Host First Quarter 2010 Corporate Highlights and Financial Results Conference Call
4. LightLab Highlights OCT Market Leadership at the Society for Cardiovascular Angiography and Interventions
5. Abbott Annual Meeting Highlights Continued Strong Performance in 2009; Sustained Growth in 2010
6. Bionovo Announces 2009 Highlights and Year-End Financial Results
7. Siemens Highlights Its Commitment to Excellence in Cardiology at ACC 2010
8. New Publication Highlights 2-Year Durability and Effectiveness of Macroplastique(R)
9. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
10. Amicus Therapeutics Announces Fourth Quarter and Full Year 2009 Financial Results and Highlights Product Pipeline Advancements
11. Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- Encision Inc. (PK:ECIA), a medical device company owning patented ... minimally invasive surgery, today announced financial results for its ... The Company posted quarterly net revenue of ... thousand, or $(0.02) per share. These results compare to ... of $202 thousand, or $(0.02) per share, in the ...
(Date:8/3/2015)... 2015  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ; ... exclusive licensing agreement to develop and commercialize multiple prespecified ... a holding company for premier antibody development and manufacturing ... Under the terms of the agreement, Sorrento will ... the North American, European and Japanese market. Each of ...
(Date:8/2/2015)... Aug. 3, 2015  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... TELESTAR Phase 3 clinical trial met its primary ... in treating cancer patients with carcinoid syndrome that ... of care. Telotristat etiprate was discovered using Lexicon,s ... is the company,s first discovery to complete a ...
Breaking Medicine Technology:Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 2Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6
... 9, 2012  The National Association of Drug ... facilitates cooperation between law enforcement, healthcare professionals, ... the prevention and investigation of drug diversion -- ... Log Exchange (NPLEx) in Kentucky is blocking ...
... MedPlast, Inc.,s ability to craft the pessary balloons ... the company,s commitment to premium quality output and complete ... Today,s pessaries are precision-manufactured medical devices that ... treat a variety of gynecologic conditions, including prolapse. In ...
Cached Medicine Technology:Kentucky Real-Time, Stop-Sale System Is Effective In Blocking Illegal Sales Of Pseudoephedrine 2MedPlast's Pessary Balloon Manufacture Showcases Multi-Function Technical Mastery 2
(Date:8/3/2015)... , ... August 03, 2015 , ... Dignity Health named ... Arizona General Hospital Emergency Room – Gilbert, opening in August. The new facility ... year in the West Valley. , “Dr. Baldwin is an excellent leader and ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... of medical information, risk management and investigative services, has introduced a new ... focused, expert information solutions that improve business outcomes for its customers. EMSI’s ...
(Date:8/2/2015)... ... ... A new Phase I research study is looking at a vaccine that hopes ... G. Lucas, M.D. , chief of the division of pediatric hematology/oncology and stem cell ... Hospital and in the UofL Department of Pediatrics . Patients are currently ...
(Date:8/1/2015)... ... 02, 2015 , ... Back packs can be dangerous? Whaaat?! , Not the ... wreck havoc on a kid's spine. With school starting again, most kids will be ... sure you are aware of how to help them prevent injuries by understanding backpack ...
(Date:8/1/2015)... ... August 01, 2015 , ... Tina Wilcoxson, owner of Freeport Maine’s Royal ... that honor by the National Retail Federation, the largest retail trade association in the ... three Maine business owners to be named as such. According to the NRF’s website, ...
Breaking Medicine News(10 mins):Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Local Retail Advocate Wins National Recognition 2
... Meet Isabel, a busy,active 50-year-old Hispanic woman who has ... son; and enjoys being a grandmother to her,daughter,s son. ... her wrist, and her doctor tells her she has ... is typical of many women like her. To ...
... Mobile Dental Clinic to Visit Delaware,Philadelphia, and Southern New Jersey ... to Area Children ... The St. Christopher,s,Foundation for Children Ronald McDonald Care Mobile ... Dental Hygiene Month,(October). The tour will include stops at the ...
... for Pulmonary Study, SOLANA BEACH, Calif., ... a firm specializing in patient recruitment for,clinical ... of Regional Recruitment,Specialists(TM) in support of recruiting ... Pulmonary Disease (COPD) for a recently initiated,clinical ...
... WASHINGTON, Oct. 1 House Republican Whip Roy,Blunt (Mo.) ... posturing and work with Republicans on crafting a real,meaningful ... to quality health care., "If Democrats are serious ... they,ll have to start working with House,Republicans to craft ...
... at ERS 17th Annual Congress -, REDWOOD ... announced the submission of a pre-market approval (PMA) ... requesting regulatory,approval to market the Emphasys endobronchial valve, ... EBV is a minimally invasive and potentially,reversible treatment ...
... Del., Oct. 1 More than 125 leaders,from ... Ann Minner, joined,together to support a multi-year, statewide ... Nation. The campaign, launched by Nemours Health,and Prevention ... of,schools, communities, health professionals, parents, and other leaders ...
Cached Medicine News:Health News:Story Reveals How Isabel and Her Family Learn About Bone Health and Osteoporosis 2Health News:Story Reveals How Isabel and Her Family Learn About Bone Health and Osteoporosis 3Health News:St. Christopher's Foundation For Children Ronald McDonald(R) Care Mobile Making Tri-State Visits to Provide Dental Care to Children at No Cost 2Health News:RESolutions Rapid Enrollment Solutions, LLC Mobilizes Team of Regional Recruitment Specialists(TM) 2Health News:Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy 2Health News:Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy 3Health News:More than 125 State Leaders - Including Governor, Lt. Governor, and Congressional Delegation - Endorse Campaign to Make Delaware's Kids the Healthiest in the Nation 2Health News:More than 125 State Leaders - Including Governor, Lt. Governor, and Congressional Delegation - Endorse Campaign to Make Delaware's Kids the Healthiest in the Nation 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: